IRIS
BRUNETTI, ORONZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.223
EU - Europa 399
AS - Asia 189
OC - Oceania 2
SA - Sud America 1
Totale 3.814
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.219
SE - Svezia 217
CN - Cina 133
IT - Italia 47
GB - Regno Unito 43
FR - Francia 28
BE - Belgio 25
VN - Vietnam 24
IN - India 18
DE - Germania 13
FI - Finlandia 7
IR - Iran 6
CA - Canada 4
CZ - Repubblica Ceca 3
AU - Australia 2
HK - Hong Kong 2
IE - Irlanda 2
JP - Giappone 2
TR - Turchia 2
UA - Ucraina 2
AL - Albania 1
AT - Austria 1
BG - Bulgaria 1
CH - Svizzera 1
DK - Danimarca 1
ES - Italia 1
KW - Kuwait 1
KZ - Kazakistan 1
MT - Malta 1
NL - Olanda 1
PL - Polonia 1
PY - Paraguay 1
RO - Romania 1
RS - Serbia 1
RU - Federazione Russa 1
Totale 3.814
Salva come PNG Salva come JPEG
Città #
Fairfield 519
Chandler 443
Woodbridge 282
Ashburn 274
Seattle 249
Cambridge 220
Houston 210
Nyköping 182
Wilmington 169
Ann Arbor 108
Dearborn 103
Lawrence 57
Roxbury 55
New York 41
Beijing 36
Des Moines 35
Brooklyn 29
Nanjing 28
Brussels 24
Dong Ket 24
San Diego 24
Bari 17
Inglewood 15
Hefei 14
Paris 14
Pune 13
Marseille 10
London 8
San Mateo 8
Jinan 7
Augusta 6
Edinburgh 6
Jacksonville 6
Kilburn 5
Kunming 5
Monmouth Junction 5
Princeton 5
Washington 5
Ardabil 4
Guangzhou 4
New Bedfont 4
Cinisello Balsamo 3
Falls Church 3
Grafing 3
Hounslow 3
Leawood 3
Los Angeles 3
Nanchang 3
Naples 3
Ningbo 3
Norwalk 3
Redwood City 3
Shaoxing 3
Shenyang 3
Verbania 3
Zhengzhou 3
Baotou 2
Boardman 2
Bologna 2
Chicago 2
Chiswick 2
Dallas 2
Dublin 2
Hangzhou 2
Hebei 2
Helsinki 2
Macerata 2
Milan 2
Mohali 2
Montreal 2
Mumbai 2
Prescot 2
Rome 2
Stockholm 2
Tianjin 2
Tokyo 2
Toronto 2
Wenzhou 2
Adelaide 1
Amsterdam 1
Antwerp 1
Asunción 1
Belgrade 1
Bend 1
Bradford 1
Brno 1
Böblingen 1
Chengdu 1
Copenhagen 1
Fiorano Modenese 1
Foggia 1
Fuzhou 1
Huzhou 1
Il-Madliena 1
Jiaxing 1
Kuwait 1
Lhasa 1
Madrid 1
Melbourne 1
Nanning 1
Totale 3.384
Salva come PNG Salva come JPEG
Nome #
Mast cells and angiogenesis in pancreatic ductal adenocarcinoma 183
Angiogenesis in adenosquamous cancer of pancreas 115
Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview 111
Targeting angiogenesis in biliary tract cancers: An open option 107
Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue 106
Strategies to improve cancer immune checkpoint inhibitors efficacy, other than abscopal effect: A systematic review 106
Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance 101
Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells 101
Inflammatory cells infiltrate and angiogenesis in locally advanced and metastatic cholangiocarcinoma 96
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol 92
CAFs and TGF-β Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer 90
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 90
Bone metastasis as primary presentation of pancreatic ductal adenocarcinoma: A case report and literature review 88
Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma 88
Emerging role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma 85
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 84
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 83
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 82
Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma 82
null 81
Long‐term survival of an advanced colorectal cancer patient treated with Regorafenib: Case report and literature review 80
Micro-RNA in pancreatic adenocarcinoma: Predictive/prognostic biomarkers or therapeutic targets? 80
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 79
Fisiologia V Ed. 78
Multimodal treatment of resectable pancreatic ductal adenocarcinoma 75
Bone metastases in biliary cancers: A multicenter retrospective survey 75
Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib 73
Molecular characterization of a long-term survivor double metastatic non-small cell lung cancer and pancreatic ductal adenocarcinoma treated with gefitinib in combination with gemcitabine plus nab-paclitaxel and mFOLFOX6 as first and second line therapy 73
The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy 73
Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors 71
Management of patients with end-stage renal disease undergoing chemotherapy: Recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Nefrologia (SIN) 69
null 67
The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following? 67
Systematic review of irreversible electroporation role in management of locally advanced pancreatic cancer 66
Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? 66
Immunotherapy for colorectal cancer: where are we heading? 63
Immunological mutational signature in adenosquamous cancer of pancreas: an exploratory study of potentially therapeutic targets 63
null 61
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 60
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 53
Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma 53
Immune system and bone microenvironment: rationale for targeted cancer therapies 45
Basics and frontiers on pancreatic cancer for radiation oncology: Target delineation, SBRT, SIB technique, MRgRT, particle therapy, immunotherapy and clinical guidelines 41
COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients? 40
Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials 40
Clinical practice guidelines for diagnosis, treatment and follow-up of exocrine pancreatic ductal adenocarcinoma: Evidence evaluation and recommendations by the italian association of medical oncology (AIOM) 38
Somatic BRCA Mutation in a Cholangiocarcinoma Patient for HBOC Syndrome Detection 37
Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies 35
The latest findings of PD-1/PD-L1 inhibitor application in gynecologic cancers 33
Expression and characterization of a novel recombinant cytotoxin II from Naja naja oxiana venom: A potential treatment for breast cancer 33
Is it Time for a Therapeutic Algorithm in Resected Pancreatic Ductal Adenocarcinoma? 30
Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma: Could Surgery Represent a Therapeutic Option? 30
Cytotoxic t-lymphocyte antigen-4 in colorectal cancer: Another therapeutic side of capecitabine 30
NLRP3 Inflammasome From Bench to Bedside: New Perspectives for Triple Negative Breast Cancer 29
On the Management of Drug Interactions in the Course of Concomitant Treatments for COVID-19 and Antineoplastic Agents 25
Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis 24
Moving the target on the optimal adjuvant strategy for resected pancreatic cancers: A systematic review with meta-analysis 22
A scoping review on the potentiality of PD-L1-inhibiting microRNAs in treating colorectal cancer: Toward single-cell sequencing-guided biocompatible-based delivery 21
Bone metastases in hepatocellular carcinoma: an emerging issue 20
The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead 20
Paraneoplastic focal segmental glomerulosclerosis in sarcomatoid renal cell cancer. 16
Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel? 3
Totale 4.028
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.401
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.401
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201957 0 0 0 0 0 0 0 0 0 0 28 29
2019/20201.244 38 25 12 72 206 174 160 180 187 76 68 46
2020/2021936 41 71 97 148 89 70 72 76 45 87 75 65
2021/2022509 42 19 13 15 20 45 17 30 37 46 68 157
2022/2023929 104 155 85 75 85 95 15 113 140 5 40 17
2023/2024275 19 59 15 28 33 95 7 9 3 7 0 0
Totale 4.028